ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,064 | +32.5% | 11,367 | +26.3% | 0.01% | +50.0% |
| Q2 2023 | $803 | -11.9% | 9,000 | +5.9% | 0.00% | -20.0% |
| Q1 2023 | $911 | +5.1% | 8,500 | +19.7% | 0.01% | 0.0% |
| Q4 2022 | $867 | -99.9% | 7,100 | -26.0% | 0.01% | -28.6% |
| Q3 2022 | $991,000 | +11.1% | 9,600 | 0.0% | 0.01% | +16.7% |
| Q2 2022 | $892,000 | -21.6% | 9,600 | -1.0% | 0.01% | 0.0% |
| Q1 2022 | $1,138,000 | -12.8% | 9,700 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $1,305,000 | -22.8% | 9,700 | -8.5% | 0.01% | -33.3% |
| Q3 2021 | $1,690,000 | +38.2% | 10,600 | +14.0% | 0.01% | +50.0% |
| Q2 2021 | $1,223,000 | +2.0% | 9,300 | 0.0% | 0.01% | -14.3% |
| Q1 2021 | $1,199,000 | -30.2% | 9,300 | -9.7% | 0.01% | -30.0% |
| Q4 2020 | $1,718,000 | +27.9% | 10,300 | +18.4% | 0.01% | 0.0% |
| Q3 2020 | $1,343,000 | -47.8% | 8,700 | -50.0% | 0.01% | -9.1% |
| Q2 2020 | $2,574,000 | – | 17,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |